Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN's market-leading QuantiFERON-TB Gold Plus (QFT-Plus). The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gam ...

The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gamma release assays (IGRAs). The new standards were published in the academy's Red Book: 2024–2027 Report of the Committee on Infectious Diseases. The AAP's recommendations follow recently updated guidelines from the American College Health Association (ACHA) stating that IGRAs are preferred over the 120-year-old tuberculin skin test (TST) for most situations relevant to college health. The upda ...

To date, QCI Interpret has analyzed and interpreted more than 4 million NGS patient test cases for oncology and hereditary diseases worldwide and processed above 850,000 clinical samples annually. It has emerged as the preferred choice for labs and organizations of all sizes globally due to its consistency, accuracy and superior content. Image Source: Zacks Investment Research NGS is changing the genomics landscape with rapid adoption and advancement within the industry. The senior vice president of QIAGEN ...

QIAGEN N.V. (QGEN) recently launched 35 new wet-lab tested dPCRs for its digital PCR (dPCR) platform QIAcuity. The new assays are available on the GeneGlobe research platform and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs). The latest development further strengthens QIAGEN's position as a leader in microbial detection and analysis. This is also likely to significantly boost its Life Sciences bu ...

Core Viewpoint - QIAGEN is committed to achieving solid profitable growth through 2028, targeting approximately 7% compound annual sales growth (CAGR) at constant exchange rates and aiming for at least a 31% adjusted operating income margin by 2028 [1][4][13]. Group 1: Financial Targets and Growth Strategy - QIAGEN plans to return at least $1 billion to shareholders from 2024 to 2028, excluding value-creating M&A opportunities [4][16]. - The company aims for at least $2 billion in combined annual sales from its growth pillars by 2028, supported by new product launches and significant investments [7]. - QIAGEN has a goal to achieve at least a 31% adjusted operating income margin by 2028, driven by efficiency initiatives and digitization [13][14]. Group 2: Product Development and Innovation - QIAGEN is focusing on the QIAcuity digital PCR system, planning to triple the number of sales specialists and launch over 100 new assays, with regulatory clearance for clinical use expected in 2024 [7]. - The company confirmed plans for new panels for syndromic diagnosis, including submissions for meningitis and other conditions by 2028 [8]. - QIAGEN Digital Insights will see at least nine new product launches by 2028, with a 40% expansion in the commercial team [9][10]. Group 3: Operational Efficiency and Digitization - QIAGEN is implementing initiatives to streamline its portfolio and improve operational margins, including the discontinuation of the NeuMoDx system [14]. - The company is pursuing about 30 AI initiatives to enhance growth and profitability [14]. - Plans include upgrading the SAP enterprise resource system to simplify organizational processes [14]. Group 4: Leadership and Corporate Responsibility - QIAGEN emphasizes the importance of a strong culture among its 6,000 employees, focusing on empowerment and accountability to achieve its 2028 targets [17]. - The company reaffirms its commitment to ESG goals, including a target to reach net zero carbon emissions by 2050 [17].

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels and higher test volumes. The latest version of QCI Interpret introduces ...

Venlo, the Netherlands, June 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2023 Sustainability Report which underscores the company's commitment to Environmental, Social, and Governance (ESG) principles, highlighting substantial achievements in its sustainability journey. "In line with our vision of making improvements in life possible, we are committed to delivering the best possible portfolio of products and services while leaving the smallest possible ...

"In line with our vision of making improvements in life possible, we are committed to delivering the best possible portfolio of products and services while leaving the smallest possible footprint on our planet. From whom we source to how we produce, we approach each step with the intention of doing so in a sustainable way. Investing in sustainable practices is not only a moral duty but also a strategic business decision that brings value to our stakeholders, including customers and employees," said Thierry ...

In addition to the product showcase, QIAGEN will present a poster on "Improved Extraction of Total Nucleic Acid from Microbiome Samples". This research highlights advancements in the extraction of DNA and RNA from human microbiome samples, focusing on methods that remove inhibitors and yield higher quality and quantity of nucleic acids. The findings underscore the importance of mechanical lysis using bead beating for efficient, unbiased extraction suitable for automation and standardization across laborator ...

The latest developments aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience. This is also likely to boost QIAGEN's Life Science business area. Image Source: Zacks Investment Research Additional enhancements of the GeneGlobe research platform have been launched recently or are currently in development, including more user-friendly design pages that simplify product selection and a new too ...